Eye care company Alcon acquires Transcend Medical
18 February 2016 | By Victoria White
This Transcend Medical acquisition also expands Alcon's leadership in glaucoma and cataract treatment...
List view / Grid view
News
Diabetes drug pioglitazone may prevent recurring strokes
18 February 2016 | By Victoria White
A new study has found that pioglitazone may prevent recurrent stroke and heart attacks in people with insulin resistance but without diabetes...
PerkinElmer Signals™ Perspectives launches in collaboration with Attivio
18 February 2016 | By PerkinElmer Inc
New data discovery solution leverages Attivio’s platform to provide insight into complex scientific challenges...
NICE calls for more research into Alexion’s sebelipase alfa
18 February 2016 | By Victoria White
NICE has published draft guidance that recommends further clinical trials are carried out to demonstrate the benefits sebelipase alfa for treating LAL deficiency...
inABLE® technology helps unlock the secrets of cyclic peptides
17 February 2016 | By Ingenza Laboratory
Ingenza is using its proprietary inABLE® technology to help develop a robust, versatile platform for the production of cyclic peptides for therapeutic use...
Praxbind (idarucizumab) reimbursed in England, Ireland and Wales
17 February 2016 | By Victoria White
Praxbind (idarucizumab) is now available to be used commercially after the Health Technology Appraisal bodies agreed that it is eligible for full reimbursment without the need for a full appraisal.
New study to investigate PQR309 and eribulin in triple-negative breast cancer
17 February 2016 | By Victoria White
Eisai and PIQUR Therapeutics are to collaborate to conduct the Phase I/IIb clinical study of PIQUR’s PQR309 in combination with Eisai’s eribulin...
Breakthrough Therapy Designation for ocrelizumab in PPMS
17 February 2016 | By Victoria White
Roche's ocrelizumab is the first investigational medicine to receive Breakthrough Therapy Designation in multiple sclerosis...
ICR scientists develop Ecosystem Diversity Index for breast cancers
16 February 2016 | By Victoria White
Scientists have developed a test called the Ecosystem Diversity Index which combines methods used by ecologists with a powerful cancer imaging technique...
FDA accepts Teflaro sNDA for filing
16 February 2016 | By Victoria White
If approved, this filing will expand the label of Teflaro beyond adults to include the treatment of children two months of age and older...
‘Extraordinary’ t-cell therapy results could change the face of cancer treatment
16 February 2016 | By Victoria White
In one study, the engineered T-cells induced complete remission in 94% of patients with acute lymphoblastic leukaemia...
Growth in Finished Dosage Formulations sees CPhI Worldwide introduce new event
16 February 2016 | By CPhI Worldwide
CPhI Worldwide formally introduces a new co-located event entirely dedicated to Finished Dosage Formulation (FDF) following a soft launch amongst exhibitors in 2015...
Golimumab shows higher treatment persistence rates in patients with IMRD
16 February 2016 | By Victoria White
A study shows that patients initiating treatment with golimumab had significantly higher persistence rates than those initiating treatment with adalimumab or etanercept at 3 years.
Amgen’s Phase 3 Aranesp trial in MDS meets primary endpoint
16 February 2016 | By Victoria White
Aranesp reduced the incidence of red blood cell transfusions in anaemic patients with low and intermediate-1 risk myelodysplastic syndrome...
Zepatier to threaten the dominance of Harvoni in the HCV market
15 February 2016 | By Victoria White
A GlobalData analyst says that the combination of Zepatier’s excellent clinical profile and highly competitive pricing will play a major role in encouraging its uptake...
